Gold nanoparticles as antiangiogenic and antimetastatic agents

Drug Discov Today. 2023 Feb;28(2):103438. doi: 10.1016/j.drudis.2022.103438. Epub 2022 Nov 12.

Abstract

Angiogenesis and metastasis are two interdependent cancer hallmarks, the latter of which is the key cause of treatment failure. Thus, establishing effective antiangiogenesis/antimetastasis agents is the final frontier in cancer research. Gold nanoparticles (GNPs) may provide disruptive advancements in this regard due to their intrinsic physical and physiological features. Here, we comprehensively discuss recent potential therapeutical strategies to treat angiogenesis and metastasis and present a critical review on the state-of-the-art in vitro and in vivo evaluations of the antiangiogenic/antimetastatic activity of GNPs. Finally, we provide perspectives on the contribution of GNPs to the advancement of cancer management.

Keywords: angiogenesis; metastasis; nanomedicine; nanoparticles; oncology; theranostics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Gold
  • Humans
  • Metal Nanoparticles* / therapeutic use
  • Neoplasms* / drug therapy

Substances

  • Gold
  • Antineoplastic Agents
  • Angiogenesis Inhibitors